238 related articles for article (PubMed ID: 28398284)
1. Manifestations and management of veno-occlusive disease/sinusoidal obstruction syndrome in the era of contemporary therapies.
Tewari P; Wallis W; Kebriaei P
Clin Adv Hematol Oncol; 2017 Feb; 15(2):130-139. PubMed ID: 28398284
[TBL] [Abstract][Full Text] [Related]
2. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation.
Dignan FL; Wynn RF; Hadzic N; Karani J; Quaglia A; Pagliuca A; Veys P; Potter MN; ;
Br J Haematol; 2013 Nov; 163(4):444-57. PubMed ID: 24102514
[TBL] [Abstract][Full Text] [Related]
3. Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: Risk Factors and Stratification, Prophylaxis, and Treatment.
Dalle JH; Giralt SA
Biol Blood Marrow Transplant; 2016 Mar; 22(3):400-9. PubMed ID: 26431626
[TBL] [Abstract][Full Text] [Related]
4. Defibrotide for Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Prophylaxis in High-Risk Adult Patients: A Single-Center Experience Study.
Picod A; Bonnin A; Battipaglia G; Giannotti F; Ruggeri A; Brissot E; Malard F; Médiavilla C; Belhocine R; Vekhoff A; Gueye MS; Lapusan S; Adaeva R; Isnard F; Legrand O; Baylatry MT; Joly AC; Labopin M; Duléry R; Mohty M
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1471-1475. PubMed ID: 29477779
[TBL] [Abstract][Full Text] [Related]
5. Risk Factors for Development of and Progression of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome.
Corbacioglu S; Jabbour EJ; Mohty M
Biol Blood Marrow Transplant; 2019 Jul; 25(7):1271-1280. PubMed ID: 30797942
[TBL] [Abstract][Full Text] [Related]
6. Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation.
Richardson PG; Smith AR; Triplett BM; Kernan NA; Grupp SA; Antin JH; Lehmann L; Miloslavsky M; Hume R; Hannah AL; Nejadnik B; Soiffer RJ
Br J Haematol; 2017 Jul; 178(1):112-118. PubMed ID: 28444784
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Circulating Endothelial Cells as Direct Marker of Endothelial Damage in Allo-Transplant Recipients at High Risk of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome.
Farina M; Scaini MC; Facchinetti A; Leoni A; Bernardi S; Catoni C; Morello E; Radici V; Frioni F; Campodonico E; Traverso G; Cavallaro G; Olivieri A; Galieni P; Renzo ND; Patriarca F; Carluccio P; Skert C; Maffini E; Pellizzeri S; Campisi G; Re F; Benedetti E; Rosato A; Almici C; Chiusolo P; Peccatori J; Malagola M; Poggiana C; Russo D
Transplant Cell Ther; 2024 Jun; 30(6):580.e1-580.e14. PubMed ID: 38582286
[TBL] [Abstract][Full Text] [Related]
8. Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation.
Roeker LE; Kim HT; Glotzbecker B; Nageshwar P; Nikiforow S; Koreth J; Armand P; Cutler C; Alyea EP; Antin JH; Richardson PG; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2019 Jan; 25(1):137-144. PubMed ID: 30081073
[TBL] [Abstract][Full Text] [Related]
9. Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study.
Richardson PG; Smith AR; Triplett BM; Kernan NA; Grupp SA; Antin JH; Lehmann L; Shore T; Iacobelli M; Miloslavsky M; Hume R; Hannah AL; Nejadnik B; Soiffer RJ;
Biol Blood Marrow Transplant; 2017 Jun; 23(6):997-1004. PubMed ID: 28285079
[TBL] [Abstract][Full Text] [Related]
10. Defibrotide for the management of sinusoidal obstruction syndrome in patients who undergo haemopoietic stem cell transplantation.
Coutsouvelis J; Avery S; Dooley M; Kirkpatrick C; Spencer A
Cancer Treat Rev; 2016 Nov; 50():200-204. PubMed ID: 27721142
[TBL] [Abstract][Full Text] [Related]
11. Molecular Advances in Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease.
Mavrikou I; Chatzidimitriou D; Skoura L; Nikolousis E; Sakellari I; Gavriilaki E
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982695
[TBL] [Abstract][Full Text] [Related]
12. Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome.
Richardson PG; Triplett BM; Ho VT; Chao N; Dignan FL; Maglio M; Mohty M
Expert Rev Clin Pharmacol; 2018 Feb; 11(2):113-124. PubMed ID: 29301447
[TBL] [Abstract][Full Text] [Related]
13. Prior Gemtuzumab Ozogamicin Exposure in Adults with Acute Myeloid Leukemia Does Not Increase Hepatic Veno-Occlusive Disease Risk after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis.
Ho VT; Martin AS; Pérez WS; Steinert P; Zhang MJ; Chirnomas D; Hoang CJ; Loberiza FR; Saber W
Biol Blood Marrow Transplant; 2020 May; 26(5):884-892. PubMed ID: 31891815
[TBL] [Abstract][Full Text] [Related]
14. Veno-occlusive disease/sinusoidal obstruction syndrome after haematopoietic stem cell transplantation: Middle East/North Africa regional consensus on prevention, diagnosis and management.
Al Jefri AH; Abujazar H; Al-Ahmari A; Al Rawas A; Al Zahrani Z; Alhejazi A; Bekadja MA; Ibrahim A; Lahoucine M; Ousia S; Bazarbachi A
Bone Marrow Transplant; 2017 Apr; 52(4):588-591. PubMed ID: 27892944
[TBL] [Abstract][Full Text] [Related]
15. Identification and Management: Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Eelated to Hematopoietic Stem Cell Transplantation
.
Ní Chonghaile M; Wolownik K
Clin J Oncol Nurs; 2018 Feb; 22(1):E7-E17. PubMed ID: 29350698
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Biomarkers for Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome in Myeloablative Allogeneic Hematopoietic Cell Transplantation: Results from the Blood and Marrow Transplant Clinical Trials Network 1202 Study.
Putta S; Young BA; Levine JE; Reshef R; Nakamura R; Strouse C; Perales MA; Howard A; Pine P; Shi J; Zhang P; Ho VT; Saber W
Transplant Cell Ther; 2023 Mar; 29(3):166.e1-166.e10. PubMed ID: 36574581
[TBL] [Abstract][Full Text] [Related]
17. Incidence of Anicteric Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome and Outcomes with Defibrotide following Hematopoietic Cell Transplantation in Adult and Pediatric Patients.
Corbacioglu S; Kernan NA; Pagliuca A; Ryan RJ; Tappe W; Richardson PG
Biol Blood Marrow Transplant; 2020 Jul; 26(7):1342-1349. PubMed ID: 32200121
[TBL] [Abstract][Full Text] [Related]
18. Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome following nontransplant-associated chemotherapy: Final results from a post hoc analysis of data from an expanded-access program.
Kernan NA; Richardson PG; Smith AR; Triplett BM; Antin JH; Lehmann L; Messinger Y; Liang W; Hume R; Tappe W; Soiffer RJ; Grupp SA
Pediatr Blood Cancer; 2018 Oct; 65(10):e27269. PubMed ID: 29873895
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplant.
Pai RK; van Besien K; Hart J; Artz AS; O'Donnell PH
Leuk Lymphoma; 2012 Aug; 53(8):1552-7. PubMed ID: 22280517
[TBL] [Abstract][Full Text] [Related]
20. Liver Stiffness Measurement Allows Early Diagnosis of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome in Adult Patients Who Undergo Hematopoietic Stem Cell Transplantation: Results from a Monocentric Prospective Study.
Colecchia A; Ravaioli F; Sessa M; Alemanni VL; Dajti E; Marasco G; Vestito A; Zagari RM; Barbato F; Arpinati M; Cavo M; Festi D; Bonifazi F
Biol Blood Marrow Transplant; 2019 May; 25(5):995-1003. PubMed ID: 30660772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
